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Increased levels of corticotropin releasing hormone (CRH) are associated with anxiety, as 
are decreased levels of serotonin (5-HT). Do 5-HT levels influence CRH production and 
anxiety? The ventral hippocampus is associated with anxiety behavior, contains cells expressing 
5-HT receptors (including 5HT7R), and extends axons into CRH producing regions of the 
hypothalamus (Jalewa et al., 2014; Jiminez et al., 2018). Therefore, 5-HT responsive neurons 
may play a role in the anxiety response and CRH production. To analyze how 5-HT may 
influence anxiety, 5dpf Danio rerio were examined following application of a 5-HT7R agonist 
(AS-19) and antagonist (SB-258179). A distance assay was used to assess physical 
manifestations of anxiety response. It is hypothesized that separate application of 5-HT7R 
agonist and antagonist should result in a decrease and increase in the anxiety response, 
respectively. Furthermore, it is hypothesized CRH levels should increase or decrease in an 









Autism Spectrum Conditions (ASCs) are common developmental conditions that affect 
social behavior, gastrointestinal functioning, sleep wake cycles, sensory perception, and anxiety 
levels. ASCs are often comorbid with anxiety conditions, ADHD, and learning disabilities. To 
understand potential causes of this condition and its comorbidities, one must consider the 
underlying neurological factors. The cortisol production pathway, also known as the stress 
pathway, may have an effect on ASC symptoms as social anxiety is often the most noticeable 
symptom of individuals on the Autism spectrum. Stress is a response to an external cause while 
anxiety is an individual’s specific reaction to stress; however, they are derived from the same 
neurological interactions. For the purpose of this paper, they will be referred to interchangeably. 
Therefore, the biological underpinnings of stress and anxiety are the primary interest of this 
study. While the stress hormone, cortisol, is widely understood, the neuromodulators and 
neurotransmitter communications within the production activation pathway are largely unknown. 
It is, however, known that stress and anxiety may be regulated by serotonin as the current 
treatments for anxiety conditions are Serotonin Reuptake Inhibitors (SSRIs) and Monoamine 
Oxidase Inhibitors (MAOIs) (Frazer & Hensler, 1999). These drugs prevent the metabolism of 
serotonin allowing more serotonin to be present in the synapse for uptake. Serotonin is often 
abbreviated as 5-hydroxytryptamine or 5-HT. For the purpose of this paper, it will be referred to 
as 5-HT. Our lab analyzes the extent to which 5-HT may be implicated in cortisol production 
and, thereby, stress behavior via cortisol production activator signal, corticotropin releasing 
hormone (CRH). 
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Part 1: Autism Spectrum Conditions 
1.1 Characteristics of ASCs 
ASCs is a more recent label applied to what had been Autism Spectrum Disorders; 
however, for the purpose of this paper, they will be referred to as Autism Spectrum Conditions. 
This new designation acknowledges the problematic language with which neurodevelopmental 
and mental 
conditions are 
referred. ASCs are 
clinically defined, 
according to the 
Diagnostic and 
Statistical Manual 
of Mental Health 
(5th ed.; American 
Psychiatric 
Association, 
2013), by persistent deficits in social communication, interaction, and restricted or repetitive 
patterns of behavior, interests, or activities. Criteria necessary to meet diagnosis include 
symptom presence in early childhood, clinically significant impairment in daily functioning, and 
the symptoms must not be better explained by an intellectual disability (American Psychiatric 
Association, 2013). Furthermore, the severity level of each case can be assessed by categories, 
“requiring very substantial support,” “requiring substantial support,” and, “requiring support,” 
which are defined by deficits in social communication and the presence of restrictive or 
Figure 1. Severity levels for Autism Spectrum Conditions. Adapted from DSM-5 (2013). 
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repetitive behaviors (Table 1). There may also be some language impairment, intellectual 
impairment, accompanying behavioral disorders or genetic conditions which must be separately 
specified in diagnosis and may require additional intervention. 
 
1.2 Prevalence and Causes 
According to a 2019 study by the Center for Disease Control (CDC), it is estimated one 
in 59 children have Autism and it is approximately four times more likely for boys to be 
diagnosed than girls. The statistical likelihood of boys having ASC over girls is highly debated 
among professionals as it is argued that due to the framing of the condition in terms of the male 
presentation of symptoms, the female presentation may not be as obvious, or may even be 
different than that of their male counterparts (Milner et al., 2019). A 2013 study (Buescher, Ci- 
dav, Knapp, & Mandell) estimates that the lifetime cost pertaining to caring for an individual on 
the spectrum without a co-occurring intellectual disability is around $1.4 million and the lifetime 
cost for an individual with a co-occurring intellectual disability increases to $2.4 million. 
Furthermore, the annual cost of caring for individuals in the United States is $137 billion. 
(Buescher, Ci- dav, Knapp, & Mandell, 2013 as cited in Dawson & Bernier, 2013). These 
estimates were based on services and support received in addition to opportunity costs and 
productivity loss.  
With such effects on daily function as displayed in ASCs, the high rates of prevalence, 
and the increased expenses in caring for an individual on the spectrum, research determining 
causes and most effective treatments is remarkably varied. Several theories, both environmental 
and genetic, have been proposed to produce ASC pathology, but many such theories have failed 
to gain significant backing by the science community. This supports the current belief that ASC 
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pathology is multifactorial. Some proposals of environmental factors that may induce symptoms 
include maternal immune activation during pregnancy and prenatal exposure to toxins (Varghese 
et al., 2018). One study suggests that five percent of genetic abnormalities corresponding with 
ASCs are caused by single gene mutations, around ten percent are duplications, inversions, 
extensive deletions, or translocations of chromosomes, otherwise known as copy number 
variants, and a majority of the genetic differences are polygenic risk factors from accumulation 
of mutations (Varghese et el., 2018). The seemingly multifactorial pathology of ASCs is thought 
to contribute to the spectrum of symptoms seen across individuals. Conversely, the expansive 
presentation of symptoms may contribute to the difficulty in pinpointing a singular cause. 
 
1.3 Identification and Treatment  
The symptoms in autism are specifically described as a continuum that is highly 
individual. This individuality makes identification and treatment difficult. However, to optimize 
outcome, it is important that the condition is identified and treated early. Identification of ASCs 
may occur as early as 18 months and is informed by developmental differences in behavior, such 
as failing to meet milestones. These milestones may include babbling and gesturing by 12 
months, use of single words by 16 months, use of two-word phrases by 24 months (Filipek et al., 
2000 as cited in Dawson & Bernier, 2013).  Physical identifiers of ASC development are often 
present around 18-12 months, such as motor delays, development of unusual repetitive 
behaviors, atypical visual attention, easily shifted or disengaged attention (Landa & Garrett-
Mayer, 2006; Iverson & Wozniak, 2007; Ozonoff et al., 2008; Zwaigenbaum et al., 2005 as cited 
in Dawson & Bernier, 2013). In addition to physical identifiers, social differences may occur, 
including deficits in social orienting, the ability to share a common focus on something with 
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another person, and imitation abilities (Mitchell et al., 2006; Nadig et al., 2007; Ozonoff et al., 
2010; Pres- manes, Walden, Stone, & Yoder, 2007 as cited in Dawson & Bernier, 2013). 
Furthermore, loss of language or motor skills at any age is an indicator of an ASC, or some other 
developmental condition, and should be treated as early as possible.  
In order to ameliorate symptoms in daily quality of living, early treatment is necessary. 
Therapy for ASCs may take the form of either a focused or comprehensive approach. A focused 
approach is an evidence-based therapy which works to ameliorate a particular symptom, while a 
comprehensive approach is one that is constructed to improve overall functioning and daily life. 
Commonly, some combination of the two approaches is utilized in treatment of ASCs to address 
specific problematic symptoms, such as excessive aggression, in addition to increasing long-term 
outcomes and daily functioning. Some current examples of popular therapy may include play 
therapy, Applied Behavioral Analysis (ABA) therapy, and Early Start Denver Model (EDSM) 
therapy. There is, however, backlash about certain treatments that are perceived as aiming to 
make people on the spectrum ‘normal’ rather than accepting the individual as neurodiverse and 
working to help the child with necessary life skills. Some other concerns about these therapies is 
they do not address longitudinal skills, like answering questions that change from year to year 
(e.g. “How old are you?”) and how to self-regulate emotional changes. Despite these critiques, 
studies still support the use of the behavioral therapeutic models available now. 
In addition to behavioral therapies, there are some pharmacotherapies which are often 
prescribed to individuals on the spectrum. Antipsychotics are often used for treatment of 
irritability in individuals on the spectrum and currently only risperidone and aripiprazole are 
approved by the FDA for use on individuals on the spectrum (Goel, Hong, Findling, & Jo, 2018). 
SSRIs are also commonly used; however, there is no current data to support beneficial impacts 
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on individuals on the spectrum who take them. However, because anxiety is such an evasive 
symptom, it is important to address pharmacologically how best to moderate its effects on an 
individual. Therefore, further research into treatment of ASCs with SSRIs is warranted. 
 
Part 2: Cortisol and Stress 
2.1 Functional Overview of Cortisol  
 Cortisol is a glucocorticoid, which is a type of steroid that functions to modulate 
carbohydrate metabolism and is released during stressful situations (Brown, 1994). In addition to 
these functions, cortisol plays a role in controlling salt and water balance within the body, 
maintaining blood pressure, influencing memory formation, and aiding in fetal development 
(McEwen, 1999). Cortisol is also involved in some immunosuppressive and anti-inflammatory 
responses (Brown, 1994). Based on its involvement in many of the body’s regulatory processes, 
it is evident that cortisol is a major contributor to healthy functioning and development; so, it’s 
dysfunction can lead to serious health issues.  
 When there is too much cortisol over a prolonged period of time, sex drive may decrease 
and menstruation may become irregular, less frequent, or even stop occurring altogether. Too 
much cortisol may also lead to a condition called Cushing’s syndrome, which is characterized by 
rapid weight gain in the upper body and face with slender arms and legs, flushed face, high blood 
pressure, easy bruising, muscle weakness, frequent feeling of thirst or need to urinate, and mood 
swings that may look like anxiety or depression (McEwen, 1999). Therefore, an increased 
cortisol can be problematic for healthy functioning. However, the reverse may also lead to 
dangerous health problems. Too little cortisol may be the byproduct of a problem in the pituitary 
or adrenal glands. Symptoms may include weight loss, fatigue, muscle weakness, dizziness, 
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mood changes, and darkening of regions of the skin (McEwen, 1999). The range of symptoms 
that occur from either too much or too little cortisol can significantly affect daily functioning and 
individual long-term health.  
There is a long-standing association between varying cortisol levels and psychiatric 
conditions, like anxiety and depression. In fact, cortisol is often referred to as the anxiety 
hormone as it is specifically associated with the stress and fear response in higher vertebrates 
(McEwen, 1999). Evolutionarily, one may understand the need for cortisol as a way to 
physiologically prepare the body to respond to nearby danger stimuli; however, in modern times, 
such primal danger is no longer present, but the bodies have not yet evolved to deal with the 
reduction in danger stimuli. This may be why human conditions like anxiety and depression 
exist. It is important to understand the neurological basis of the cortisol pathway and analyze 
how it functions in animal models to better understand 
how to treat these conditions. There are several behavioral 
paradigms often used in laboratory settings to indicate 
levels of increased anxiety, stress, or fear as they all have 
similar biological derivatives. These paradigms include, 
but are not limited to, exploratory behavior, freezing, and 
startle responses (Schulkin, 1999). Exploratory behavior 
can be assessed by introducing an animal into a novel 
arena and assessing distance moved. Freezing behavior 
can be assessed at the same time as exploratory behavior 
in some cases and is marked by the inability to move. 
Startle responses can be measured by introducing some 
Figure 2. Cortisol production stimulated by 
stressor. Modified from Alschuler (2016). 
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stimulus and analyzing the degree to which a known response is met (e.g. c-turn in zebrafish). 
With these paradigms, much about cortisol’s behavioral effects can be learned and then applied 
to treatment of human conditions.  
               
2.2 The Cortisol Production and Metabolism Pathway 
 Cortisol production begins when CRH in the paraventricular nucleus (PVN) of the 
hypothalamus is released which in turn signals the release of adrenocortical hormone (ACTH) in 
the pituitary gland (Figure 2). All subsequent chemical reactions to produce cortisol are 
catalyzed by enzymes. Cholesterol in the zona fasciculata layer of the adrenal cortex is signaled 
by ACTH to become chemically modified via enzyme into pregnenolone (Dhillo et al., 2002 as 
cited by Jones, 2017). Cholesterol, depending on in where it is found in the adrenal cortex and 
what enzymes are present, can make any steroid (McEwen, 1999). All steroids initially come 
Figure 3. Biological pathway map of cholesterol forming steroid products. Cortisol production is 
highlighted in blue. Boldface and underlined words indicate layers of adrenal cortex. Adapted from 
Ortsater, Sjoholm, & Rafacho (2012). 
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from pregnenolone and then diverge into their respective pathways via specific enzymes (Figure 
3). In the case of cortisol, pregnenolone is then catalyzed by an enzyme to become 17-OH 
pregnenolone, then 17-OH progesterone, followed by 11-deoxycortisol. Finally, cortisol is 
produced and released in the adrenal gland (Ortsater, Sjoholm, & Rafacho, 2012). After 
production, cortisol negatively affects the production of CRH and ACTH to stop further 
production of cortisol.  
Steroids, including cortisol, when released, freely diffuse from the cell and through the 
phospholipid bilayer of another cell to a receptor within the cytoplasm of the receiving cell. The 
receptor/steroid complex then moves into the nucleus and functions as a transcription factor for 
particular genes (Figure 4; McEwen, 1999). This differs from other types of cell signaling which 
requires cell surface receptors, and the signal itself acts as a transcription factor rather than 
needing a receptor complex to enact change within gene expression. Following its production, 
cortisol is metabolized into 5-alpha-Tetrahydrocortisol and 5-beta-Tetrahydrocortisol (Jones, 
2017). Often, cortisol and corticosterone are referred to synonymously; however, it is important 
to note that they are not chemically the same, but 
instead serve the same function within different 
organisms. Cortisol is found in humans, fish, and most 
other mammals while corticosterone is found in rats, 
mice, birds, and reptiles (McEwen, 1999).  
 In research settings, it is important to be able to 
detect cortisol level; however, it is often difficult to do 
so in smaller organisms. In mice, rats, monkey’s, and 
even humans it is common to detect cortisol by 
Figure 4. Steroid action in cell. Steroid binds 
intracellular receptor and is then transferred to 
nucleus as a receptor-hormone complex to activate 
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analyzing blood plasma or taking salivary samples (Lim, 2013). This procedure has also been 
done in fish, but in developmental research, the use of larvae or early staged embryos make 
collection of blood plasma difficult, as there is so little blood present to obtain data for analysis. 
For this reason, CRH can be used to detect presumed cortisol production. The metabolites of 
cortisol can also be analyzed to approximate cortisol production. (Olivereau & Olivereau, 1987) 
 
Part 3: 5-HT and Cortisol Regulation 
3.1 Functional Overview of 5-HT 
 Serotonin, or 5-hydroxytryptamine (5-HT) is a neurotransmitter that is involved in a 
variety of functions including regulating the sleep/wake mechanism and eating behavior, 
gastrointestinal activity, social dysfunction, depression, and 
anxiety as well as some neuroendocrine regulatory activity (Frazer 
& Hensler, 1999). 5-HT is a monoamine, meaning it only has one 
amine group attached to its catechol ring and is considered a part 
of the catecholamine family of neurotransmitters (Figure 5). It is 
synthesized from L-tryptophan which is hydrolyzed to form 
hydroxytryptophan. Hydroxytryptophan is then decarboxylated to 
form 5-HT (Figure 6). After its production, 5-HT can either be 
catabolized to form 5-hydroxyindoleacetic acid or can be chemically modified to produce 
melatonin (Figure 6). 5-HT functions similarly to other amine transmitters and is released in a 
vesicle exocytotically into the synapse of a neuron and then interacts with its receptor on the 
postsynaptic membrane (Frazer & Hensler, 1999). It should be noted that there are 14 different 
known 5-HT receptor subtypes, all of which have g-protein coupled receptors with the exception 
Figure 5. 5-HT chemical structure. 
Catechol (blue) attached to 
pentagonal hydrocarbon (red) with 
amine group (yellow). Image 
modified from Psychedelic Science 
Review. 
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of the 5-HT3 subtype which is a ligand-gated ion channel receptor. The different receptor 
subtypes are differentiated by their localization in the central nervous system (Frazer & Hensler, 
1999). The known localization of each 
receptor subtype can help in finding novel 
drug targets for several conditions in which 
particular areas of the brain may be affected.  
 
3.2 A Proposed Role for 5-HT in an 
Anxiety Pathway 
 5-HT is commonly associated with 
anxiety and is often used as a drug target for 
treatment of associated conditions. As 
cortisol and 5-HT are both implicated in 
stress and anxiety, it is reasonable to suggest 
there may be some interaction between them. 
5-HT axons have been shown to be found in several areas of the brain which connect with the 
signaling pathway that leads to cortisol production. The VCA1 of the hippocampus and the 
lateral hypothalamic area (LHA) both show presence of 5-HT and axons from the LHA extend to 
the hypothalamus where CRH is produced 
(Figure 7; Jalewa et al., 2014; Jimimez et al., 
2018). It is then reasonable to assume that 5-
HT may have some interaction with CRH 
production and may thus have some 
 Figure 6. Serotonin synthesis and catabolism with chemical 
structure. Serotonin is also the precursor to melatonin in the 
pineal gland. Image adapted from Frazer & Hensler (1999). 
  
 
Figure 7. 5-HT axons present in the anxiety pathway 
that interacts with cortisol production pathway. 
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regulatory effect on cortisol production. 
 
3.3 Targets for Manipulation 
 It is known that 5-HT stimulates 
the HPA axis; however, the exact sites of 
action are not well understood. In a 2013 
study (Lim, Porteus, & Bernier), this lack 
of understanding was addressed via 
different intravenous agonist and 
antagonist treatments in goldfish. The 
agonist targeted 5-HT1A receptor subtype 
as well as the 5-HT7 receptor subtype. To 
address the agonist’s ability to act on both 
receptor subtypes, separate antagonists for 
the 5-HT1A and 5-HT7 receptor subtypes 
were used. Following the treatment, ACTH and plasma cortisol levels were assessed. It was 
found that the 5-HT1A/7 receptor subtype mediated the largest effect. If the treatments had an 
effect on cortisol release rate, it would be expected that there would be an increase fold change 
of cortisol and the antagonist would cause a decrease in fold release rate, which is exactly what is 
shown. Based on these findings, we chose to further analyze the 5-HT7 subtype (Figure 8). 
 
 
Part 4: Anxiety and Response in Teleosts 
Figure 8. Data from Lim, Porteus, & Bernier (2013) study that 
indicates effect of 5-HT1A/7 (A) agonist and 5-HT1A 
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4.1 Teleosts as a Model System  
In order to study and manipulate aspects of neural function that impact CRH/cortisol 
production, a model species, such as Danio rerio, must be used. The balance between simplicity 
of care and system complexity is well addressed by the zebrafish model. Zebrafish development 
is relatively fast, making it ideal for manipulation. By around five days post fertilization (dpf), 
Danio rerio larvae will have formed the 
entire body plan and have all basic organ 
structures in place; therefore, making them 
suitable for manipulation before adulthood is 
even reached (Kalueff et al., 2014). This 
early ability to manipulate gene expression, 
environmental conditions, or other 
conditions make zebrafish valuable to the 
scientist as they can be bred and 
experimented on quickly, allowing for high data production rates. They are also small in size, 
making them easy to house. Danio rerio maintenance is relatively simple in that they can be kept 
in tanks with other fish so socialization does not need to be managed by experimenters. Feeding 
and light cycles can be easily controlled. Zebrafish, however, also have relatively complex 
nervous systems that resemble human systems so they can be used as a model organism. The full 
genome of Danio rerio is known so they are highly genetically traceable, and approximately 
70% of the human genome is orthologous to zebrafish genes (Figure 9, Howe et al., 2013). It is 
estimated that 82% of homologous zebrafish genes are orthologous to human genes that encode 
for disease-causing proteins (Shams et al., 2018). With such a high degree of similarity, it is 
Figure 9. Number of orthologous genes shared between 
human (red), mouse (yellow), chicken (green), and 
zebrafish (blue). Adapted from Howe et al. (2013).
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reasonable to assume that zebrafish genes may generate products that serve similar functions to 
those in humans. Furthermore, teleost species serve as an excellent model for human functioning, 
as the organization of brain structure is similar to that of humans (Kalueff et al., 2014). Zebrafish 
have all of the principle neuromediator systems which include synthesis and metabolism 
enzymes and neurotransmitter receptors (Kalueff et al., 2014). The genetic and physical 
similarities between zebrafish and humans further serves to support the continued use of Danio 
rerio in modeling of human conditions to determine pathology and novel pharmacotherapy. 
 
4.2 Cortisol Production in Zebrafish 
Current research suggests that Danio rerio cortisol response is correlated with stress 
behavior, as in humans (Kalueff et al., 2014). This is largely due to the evolutionary conservation 
of nervous system 
structures and 
endocrine tissues. 
Similar to humans, the 
teleost brain responds 
to stress by producing 
corticotropin releasing 
hormone (CRH) in the 
hypothalamus, specifically the hypothalamic nucleus preopticus (NPO). CRH then signals the 
production of adrenocortical hormone (ACTH) in the pituitary, which stimulates the production 
of cortisol from the head kidneys (Flik, Klaren, Van den Burg, Metz, & Huising, 2006). The 
head kidney is part of the interrenals in zebrafish, which functions similarly to the adrenals in 
Figure 10. Comparison of zebrafish HPI axis (a) and human HPA axis (b). Adapted from 
Collier A.D., Kalueff A.V., Echevarria D.J., 2017.
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humans. Likewise, the stress response is regulated by the hypothalamic-pituitary-interrenal (HPI) 
axis, instead of the hypothalamic-pituitary-adrenal (HPA) axis in higher vertebrates (Figure 10).  
While cortisol production in Danio rerio mirrors that of human cortisol, there are several 
key differences. An important difference between teleost species and higher vertebrates is that 
CRH-containing cells in the NPO extend axons directly to the pituitary gland, whereas teleosts 
use localized release is more common. Therefore, higher vertebrates rely on receptors in the 
target area and fish rely on CRH-sending neurons to confer specificity (Flik et al., 2006). 
Another key difference in the cortisol production pathway is the method in which activation 
occurs. While teleosts may respond to perceived environmental threats in a way that mimics 
higher vertebrates, teleosts are also subject to alarm pheromones, which are pheromones secreted 
by their predators (Lim, 2013). Humans may not be as susceptible to, or even be able to detect, 
pheromones in this way and it should be considered that teleost species may have evolved to 
respond to predatory behavior more than humans when research is conducted on these subjects. 
Despite these differences, the cortisol production pathway in Danio rerio and other teleost 
species is still considered a useful model for human behavioral and neurodevelopmental 
conditions. 
 
4.3 Zebrafish Models of Stress 
 Utilizing zebrafish for ASCs and anxiety disorders is extremely attractive because 
zebrafish behaviors associated with these conditions have been clearly defined. Recently, there 
has been a shift towards creating a comprehensive catalog of measurable behaviors and their 
relation to human behavior. Some assays associated with anxiety behavior are the c-turn assay, 
the novel tank assay, the light/dark assay, and measuring distance moved after a stimulus 
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(Kalueff et al., 2013). The c-turn assay consists of producing a stimulus and then analyzing the 
degree to which the organism turns in its escape maneuver. The higher the degree of the turn 
correlates with higher anxiety. Similarly, when a fish is placed in a novel tank, a sign of 
increased anxiety is the tendency to stay towards the bottom of the tank. Distance from the 
bottom can be measured to identify anxiety levels. The light/dark assay functions under a related 
premise, that a more anxious fish will tend to spend the majority of its time on the darker side of 
the tank rather than the lighter side and the amount of time spent in the dark versus the light can 
be measured as an indicator of stress. Finally, zebrafish tend to move away from a perceived 
threatening stimulus and the distance to which the fish moves away from the stimulus may 
indicate stress levels (Kalueff et al., 2013) There are several other stress and anxiety behaviors 
known that can be used to measure perceived stress which may be useful in further research. 
 
Part 5: Hypothesis and Objectives 
 Stress and anxiety can cause a multitude of behavioral and mental problems that affect 
daily quality of life and may contribute to some symptoms in ASCs. It is known that 5-HT plays 
some role in anxiety and the production of cortisol, the stress hormone. It is with this in mind 
that the purpose of this study is to analyze how manipulation of the serotonergic system affects 
cortisol and, consequently, behavior in the model organism Danio rerio.  
 In order to address the implications of 5-HT in the production of cortisol and stress 
behavior, we used bath application of 5-HT7 receptor subtype agonist and antagonist on 5 dpf 
larvae after which behavior was analyzed through a series of behavioral assays, including c-turn 
and distance moved after stimulus, as well as immunoprecipitation to quantify the amount of 
CRH produced. It is hypothesized that with separate application of 5-HT7R agonist and 
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antagonist, there should be a decrease and increase in anxiety behavior respectively. 
Consequently, CRH levels should increase or decrease inversely compared to anxiety behavior. 
Thus, my research aims to provide a potential cause of anxiety behavior in ASCs by addressing 
5-HT’s role in the endocrine stress response in Danio rerio and addressing other possible 




AB wildtype-strain Danio rerio were obtained from ZIRC (Zebrafish International 
Resource Center, Eugene, OR, USA) and housed at 28.5°C with 10 hours dark, 14 hours light 
cycle. Zebrafish mating pairs were housed in separate 2.8 L tanks (Aquaneering, San Diego, CA, 
USA) and fed TetraMin tropical flakes (Blacksburg, VA, USA) every 12 hours and as needed for 
matings. The Pentair Shurflo water pump (Minneapolis, MN, USA) and Aquaneering water filter 
system (San Diego, CA, USA) were used to provide continuous flow of filtered, aged tap water. 
Mating were set 5-7 hours before the dark cycle was scheduled to begin. Males and females were 
placed in a mating tank separated by a clear divider. The divider was removed at the beginning 
of the next light cycle. Embryos were then collected and incubated in 1x E3 buffer at 28.5°C. 




 Agonist, AS-19 (Tocris, 1968), and antagonist, SB-258719 (Tocris 2726), were 
reconstituted in DMSO to 1 mM and stored at -20ºC until use. Five dpf larvae were treated with 
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62.5 uM agonist or antagonist for 22 hours at 28ºC (Lim, Porteus, & Bernier, 2013). DMSO 
alone was applied at the same concentration as that of the agonist and antagonist treatment to 
account for any potential effects of the solvent on embryo development. A control of 1x E3 
buffer was also used. 
 
Behavioral Assays 
 Following 22-hour incubation in treatment condition, single larvae were pipetted into 
individual wells of a 48-well plate and subjected to an auditory stimulus placed beneath the plate 
to analyze anxiety level. Specimen movement in response to auditory stimuli is used as a 
measure of anxiety level (Kalueff et al., 2013) The auditory stimulus was created using Garage 
Band (Apple). Response to the stimulus was 
filmed from above using an Edgertronic High 
Speed Camera. See Appendix I for further details 
about camera procedures. Larvae anxiety level 
was correlated with distance moved after audio 
stimulus. Distance moved was analyzed by using 
PHET (University of Colorado Boulder) and 
calculating the difference between coordinates. 
Averages of each larvae’s movement were then 
calculated in Excel and plotted accordingly. Statistical comparison between treatment groups 




Figure 11. Camera and audio set up for 
behavioral analysis. Speaker was placed 
below the 48-well plate and response after 
stimulus was recorded. 





 A whole-body protein extract was produced from approximately 30 larvae homogenized 
in a chilled homogenizer in 1X RIPA buffer containing protease inhibitors. BCA assay was used 
to determine concentration of protein present within each sample. Protein extraction was then 
diluted and prepared for SDS-PAGE with sample buffer. Protein samples were run for 
approximately one hour at 106 volts. The gel was then transferred to PVDF membrane for 
immunoblot with anti-CRH rabbit polyclonal antibody (Boster Bio, A00629) and anti-GAPDH 
mouse monoclonal antibody(ABCAM, ab8245), as well as anti-rabbit IgG CF488 (Sigma 
SAB4600234) and anti-mouse IgG CF594 (Sigma SAB4600110) secondary fluorescently tagged 
antibodies. Membranes were imaged immediately following incubation using a UVP Imaging 
System. See Appendix II for further details on protocol. 
 
Immunoprecipitations 
 Following a 22-hour incubation in treatment condition, approximately 30 larvae per 
condition were homogenized in a chilled homogenizer and whole-body protein was extracted in 
1X RIPA buffer containing protease inhibitors. Protein extract was then immunoprecipitated 
with anti-CRH rabbit polyclonal antibody (Boster Bio, A00629) at a 1:100. Protein extract was 
also immunoprecipitated with anti-GAPDH mouse monoclonal antibody (ABCAM, ab8245) at a 
1:1000 dilution as a control. Subsequently, Protein A sepharose was added for precipitation of 
the antibody and associated protein. Immunoprecipitants were separated gel electrophoresis 
using SDS-PAGE (BioRad, 4561083) for one hour at 106 volts. Following gel electrophoresis, 
protein was visualized using Silver Stain (Boster Bio, AR0171) following manufacturer protocol. 
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Images of silver stains gels were procured via a UVP gel imaging system and analyzed 
for differences in optical density between bands as a way to evaluate levels of protein present. 
Each band was analyzed using FIJI (Schindelin, Arganda-Carreras, & Frise, 2012). Background 
density was subtracted from each band to reflect accurate optical density. Visual comparisons 




Effect of 5-HT Agonist and Antagonist on Behavior 
 Behavioral responses to auditory stimulus of 12 specimen per treatment condition for 
four separate trials were recorded and analyzed to assess the degree to which anxiety behavior 
was affected following treatment by agonist or antagonist. Responses were observed at two time 
points, 15 minutes post application and 22 hours post application. Individual larvae moved more 
in control treatment than agonist or antagonist treatments (Figure 12). Additionally, at 22 hours 
post application, there is an increase in movement for antagonist treated larvae compared to 
agonist treated larvae. However, no movement data were collected for DMSO because they died 
upon application.  
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 To assess statistical significance of observed differences in distance moved, averages of 
each treatment condition were taken and analyzed by two-tailed pairwise t-test (Figure 13). T-
test results indicated that there was statistical significance between the control treatment and the 
agonist (p = 2.9 x E-5), the control treatment and the antagonist (p = 0.00011), and between the 
agonist and antagonist (p = 6.8 x E-5). While statistical significance was indicated between 
untreated control and other treatments, the DMSO control, resulted in death and, therefore, zero 
movement. Thus, only the comparison between agonist and antagonist can be addressed as 
significant because they were treated with the same concentration of DMSO. The significance 
observed between agonist and antagonist is consistent with our hypothesis and further 
A  
B   C  
Figure 12. Individual larvae distance moved after audio stimulus. Treatment conditions include control (A), Agonist, 
AS-19 (B), and Antagonist, SB-258179 (C). It should be noted that larvae treated with the same concentration of DMSO 
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replications should be done to address the effect of the solvent used for reconstitution on 
behavior in addition to the effect of agonist and antagonist on behavior. 
 
Protein Analysis of 5 dpf Larvae 
Western Blots 
 Initial attempts to detect changes in CRH levels used fluorescent Western blot analysis 
with wild type larvae.  A number of variables were altered in numerous experiments, but there 
was no condition in which CRH protein was detected nor was the constitutively expressed 
protein GAPDH. To ensure the imager could detect the fluorophores used, dot blot tests using 
secondary antibodies were conducted. Fluorescence was observed in these tests for blots rinsed 
in TBST before addition of antibody (Figure 14).  
 Following evidence the imager could detect the fluorophores being used, we tested 
several different loading amounts of protein to assess whether there was not enough protein 
present. None of the amounts use resulted in detection of protein. It was then considered that 
 
Figure 13. Average distance moved after audio stimulus per treatment. Time at data collection were 
15 minutes (blue) and 22 hours (red) post application. Statistical significance is indicated by * for a p-
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freezing the extract affected protein antigenicity. We repeated treatment assays in order to 
compare fluorescent western blot analysis using fresh and frozen samples. Once again, no 











 Immunoprecipitation was used as a second method to detect changes in CRH levels. 
Previously prepared protein extracts (which were stored at -80ºC) from specimens used in 
behavioral assays were incubated with anti-CRH and anti-GAPDH antibodies followed by 
immunoprecipitation with Protein A sepharose. Immunoprecipitants were separated by SDS-
PAGE and silver stain was done to visualize proteins. Although protocols indicated that protein 
extract could be frozen at -80ºC or used immediately following extraction, initial results detected 
little protein (data not shown). To make a direct comparison between frozen protein extract and 
fresh protein extract, two immunoprecipitations were run, one with frozen protein extracts and 
one with fresh protein extracts. Immunoprecipitation conditions were run at the same time, 
following the same protocols, and using the same reagents. It was found that the protein extracts 
A    B   
Figure 14. Dot blot test for Western blot. Whitefield image of dot blot (A) with methanol rinse 
before antibody addition (1), TBST rinse before antibody addition (2), and dry then TBST rinse 
before antibody addition (3). Fluorescent image of dot blot (B). Fluorescence is observed only 
with the A2 method.  
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lost antigenicity after freezing (Figure 15). Therefore, following immunoprecipitations were 
begun with fresh extracts. 
Treatments were repeated to generate fresh protein extracts to begin subsequent 
immunoprecipitations. In an effort to maximize the number of immunoprecipitations that could 
be analyzed, samples, after immunoprecipitation but before separation by SDS-PAGE and silver 
stain, were placed in sample buffer and stored at -80ºC. However, silver stain of gels with 
samples treated in this way detected no proteins other than the protein markers. Treatments were 
one again repeated and generation of protein extracts, immunoprecipitation, SDS-PAGE, and 
silver stain were done in succession without storing samples at any step. To maximize use of the 
protein extracts generated, both anti-GAPDH and anti-CRH antibodies were added 
simultaneously to these extracts. Unfortunately, a loading error with marker proteins affected gel 
quality. After silver stain of this gel, IgG (about 50 kD) and GAPDH (about 37 kD) were clearly 
visualized, and, to a lesser degree, it appears some CRH (about 23 kD) was detected (Figure 16). 
Plans were to repeat the procedure, but, due to time constraints, no further repetitions of 
treatments and immunoprecipitations were possible to try and resolve inconsistent results.   
A  B  
Figure 15. Immunoprecipitation with frozen protein extract (A) versus immunoprecipitation with fresh 
protein extract (B). Faint band in A indicate IgG at approximately 50 kDa, while clearer bands in B indicate 
IgG at approximate 50 kDa and CRH at approximately 23 kDa. 
 
















 To assess potential differences in CRH expression between agonist and antagonist treated 
specimens, we used FIJI to analyze the optical density of the bands from the 
immunoprecipitations of Figure 15B (Figure 17). Because of loading problems in Figure 16, only 
Figure 15B was analyzed. Since the same dilution of IgG was used for all samples, the optical 
density of IgG bands was used as a reference for comparison to CRH bands by generating a ratio. 
Differences in optical density were observed. CRH levels in agonist treated specimens was lower 
than untreated controls and antagonist treated specimens. CRH levels in antagonist controls were 
higher than untreated controls and agonist treated specimens. DMSO specimens had the lowest 
level of CRH protein. It should be noted these are preliminary results from a single experiment; 
 
Figure 16. Overloaded immunoprecipitation following procedure observed in 
Figure 15B. IgG is observed at approximately 50 kDa and GAPDH is 
observed at approximately 37 kDa. 
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therefore, due to lack of replications, significance cannot be obtained from this data. The 










 This study aimed to investigate the potential role 5-HT plays in modulating the anxiety 
pathway, the effects of increased or decreased 5-HT activity on anxiety behavior and, more 
specifically, how its activity via the 5-HT7 receptor subtype affects production of the cortisol 
activation pathway precursor, corticotropin releasing hormone. Anxiety behavior was assessed 
based on measured distance moved after a sound stimulus with greater movement indicating 
more anxiety and protein detection CRH production was assessed by immunoprecipitation 
combined with SDS-PAGE and silver stain after it was determined that Western blot analysis 
would not provide the level of sensitivity needed to detect protein in the experimental conditions 
used for this study.   Although preliminary results were not sufficient for analysis of statistical 
significance and could not be reproduced because of time constraints, the data obtained warrants 
future study.  
 
Control DMSO Ag Ant 
IgG 
134875 137824 117106 131966 
CRH 
48126 27248 26561 64853 
Ratio 
CRH:IgG 
0.35681928 0.19770142 0.22681161 0.49143719 
Figure 17. FIJI densitometry analysis of observed bands from immunoprecipitation in 
Figu15B. Numbers represent FIJI’s measurement of optical density based on pixel 
intensity. 




Behavioral Implication of 5-HT7R Agonist and Antagonist on Anxiety 
Behavioral responses to auditory stimulus suggest anxiety behavior in zebrafish larvae is 
affected by changes in 5-HT activity (Figure 13). When comparing the distance traveled in 
response to the sound stimulus for agonist treated and antagonist treated larvae, there is no 
notable difference 15 minutes after treatment, but there is a statistically significant difference 22 
hours after treatment. The difference detected is consistent with the hypothesis that increased 5-
HT activity mimicked by the agonist would result in lower anxiety levels and decreased 5-HT 
activity mimicked by the antagonist would result in higher anxiety levels. However, both agonist 
and antagonist treated larvae exhibited less distance moved than untreated control larvae. While 
this might be expected for agonist treated it was not expected for antagonist treated larvae. 
Recognizing that the DMSO solvent used to reconstitute the agonist and antagonist may have an 
effect on the larvae, a DMSO only treatment control was included in the behavioral experiments. 
However, no movement data were collected for DMSO because they died upon treatment. This 
was an unexpected result because the concentration of DMSO used was the same concentration 
of DMSO present in the agonist and antagonist treatments. The apparent lethality of DMSO only 
treatment may be explained by the source of DMSO used. There were two bottles of DMSO 
available, and it is possible that one bottle had been used to reconstitute the agonist and 
antagonist and, when that bottle had run out, the other, older bottle had been used for the 
behavioral assays. Because of this, the data observed here may only be considered as preliminary 
and further testing is required to assess effects of DMSO on behavior before conclusions can be 
drawn.  
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CRH Production Analysis on 5dpf Larvae 
Western Blots  
Initially, fluorescent Western blot analysis was chosen as a method for detecting protein 
so that we could visualize both the target protein, CRH, and a constitutively expressed control 
protein, GAPDH, simultaneously from the same specimens. Since GAPDH is an enzyme 
involved in a basic metabolic pathway that is common to all living cells, the amount of it present 
should not be affected by the agonist and antagonist treatment. Therefore, GAPDH protein levels 
can serve as a control by which changes in CRH protein level can be compared.  
For initial experiment undertaken to optimize the method, due to short shelf-life of 
agonist and antagonist once reconstituted, only wild type larvae were used. Initial failure to 
detect protein with fluorescence pushed us to examine potential variables which may have 
affected the procedure. We tested several different theories as to why we didn’t detect protein, 
including fluorescent antibody dot blot tests, concentration of loaded protein, and frozen versus 
fresh protein extract. The UVP gel imaging system is equipped with filters to detect fluorophores 
in the green and red range. To ensure the fluorescently tagged antibodies could be detected by 
the imaging system, we added each antibody to a dry PVDF membrane and viewed in the 
imager. Fluorescence was detected, confirming we were using the correct fluorophores. 
Subsequently, we analyzed several PVDF membrane treatment conditions used in different 
protocols for immunoblotting. These treatments included methanol rinse before antibody 
addition, TBST rinse before antibody addition, and allowing membrane to dry then TBST rinse 
before antibody addition. The second method produced the best results for dot blots (Figure 14). 
This method was used for all following Western blots. We also tried using several dilutions of 
protein to sample buffer, including 1:1000, 1:100, 1:10, and pure protein extract. No dilution 
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resulted in presentation of bands. Finally, comparison of fresh versus frozen protein extracts 
resulted in no detection of bands. Repeated failure to detect protein using the fluorescence 
western blotting technique led us to believe that the level of sensitivity of this method was not 
sufficient to detect CRH or GAPDH in our samples. 
 
Immunoprecipitations 
 Since the need for a protein detection method that was more sensitive than fluorescent 
Western blot was apparent, we decided to use immunoprecipitation combined with SDS-PAGE 
and silver stain. The initial immunoprecipitation protocol needed to be optimized for our 
experiments as the protocol indicated several time points at which samples could be frozen. We 
attempted the protocol several times with freezing following protein extraction. Freezing 
following immunoprecipitation, and with fresh extract. Results indicated that using fresh protein 
extract led to the most visible bands during SDS-PAGE. However, because the process was 
rather lengthy, it was difficult to complete it with the most optimized protocol within the time 
constraints. Furthermore, because the protocol required the use of fresh protein extract in order to 
detect proteins, it was not possible to use the frozen extracts obtained from specimen used in the 
behavioral assays.  Due to time constraints, we were unable to complete treatments with 
behavioral analysis followed by immunoprecipitation. We were also unable to complete all 
planned immunoprecipitations, so the data presented in this paper are very preliminary. 
However, results from one completed immunoprecipitation analyzed by densitometry indicate 
the hypothesized decrease in CRH levels in agonist treated larvae and increase in CRH levels for 
antagonist treated larvae.  
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Due to problems with the DMSO control data, these comparisons only provide 
preliminary evidence that 5-HT may be functioning as we hypothesized and more strongly 
necessitates the need for continued research. Furthermore, the differences in simultaneous 
detection of CRH and GAPDH indicate further optimization may be needed to improve the 
efficacy of the current procedure. In addition, immunoprecipitations should be completed on 
specimens that have undergone behavioral analysis to provide more accurate data on the effect of 
treatment on 5dpf larvae. Finally, use of densitometry data should be done as well to quantify 
differences in optical density of the observed bands for each treatment.  
 
Future Research and Implications 
While this project produced no decisive conclusion of 5-HT effect on production of CRH 
and anxiety behavior, some evidence from the agonist and antagonist treated specimen does 
suggest 5-HT functions in the way hypothesized. This study provides preliminary data that 5-HT 
activity via the 5-HT7 receptor subtype may have some modulatory effect on production of CRH 
and anxiety behavior, but further testing is required to come to a decisive conclusion. With this 
in mind, research to assess the role which 5-HT plays in the anxiety pathway should continue. 
Furthermore, should these preliminary results be confirmed, expansion of this project into other 
functions affected by ASC would be called for to determine the role which 5-HT may play in the 
production of these symptoms. Areas for future research could include 5-HT functioning in the 
gastrointestinal tract, 5-HT modulation of sleep behaviors, and assessment of the role 5-HT plays 
in modulating social behaviors that lead to social dysfunction.  
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Appendix I: Camera Procedure 
Camera Set Up and Filming Procedure 
1. Plug in computer cart to wall 
2. Plug camera into wall - the camera port is on the upper right side of the camera when 
looking through the eyepiece, under a flap 
3. Connect camera to computer via firewire - camera port is under a flap on the bottom next 
to the screen and the computer port is on the left side 
4. Open iMovie on computer 
5. In iMovie, right click on left side, click create new event 
6. Click import under new event 
7. Click Sony camera 
8. On camera, click record 
9. In iMovie, click import on bottom right hand of screen to start recording 
10. Click Stop import in iMovie to stop recording 
11. Click stop recording on camera  
12. Ex out of iMovie import screen 
13. Click folder that film was recorded too 
14. Edit movie if necessary 
15. Click share in top right corner of screen to file 
16. Save movie 
17. Upload to OneDrive and email to computer with Fiji application 
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To Rewind Camera 
1. Use on/off switch to switch camera setting to play/edit 
2. Click rewind on lower left corner of screen 
3. Rewind to 00:00:00 
4. Switch back to tape 
5. Continue recording 
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Appendix II: Western Blot and BCA Procedure 
Western Blot Procedure 
 Protein Extraction 
1. Make 2x RIPA Buffer, 2x Protease Inhibitor, 5x Sample Buffer, and 10x Running Buffer 
before beginning process (See recipe list). Put homogenizer on ice. Begin heating block 
to 95 degree C if using protein extract immediately 
2. Add Tricaine to petri dish w/ larvae (see tricaine procedure on wall) 
3. Transfer larvae to eppendorf tube and remove excess E3 buffer 
4. Mix 70 microL Protease Inhibitor and 70 microL 2x RIPA buffer to separate eppendorf 
tube (for 30 bros) 
5. Add ~120 microL of RIPA mixture to eppendorf containing larvae 
6. Remove larvae and RIPA mixture and add to homogenizer on ice 
7. Homogenize larvae 
8. Remove homogenized larvae and place in eppendorf 
9. Centrifuge for 30 minutes at 13000 G at 4 degree C 
10. Remove supernatant and place in new eppendorf tube. This can either be used 
immediately or stored at -80 degrees C 
 
Gel Electrophoresis 
1. Before beginning, pull gel out to thaw, pull out sample buffer to thaw, heat block to 95 
degrees C, make 1x Running Buffer from 10x stock 
2. Make specific protein extract concentrations. For this experiment: 
a. 10 microL milliQ, 5 microL sample buffer, and 5 microL protein extract 
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b. 5 microL milliQ, 5 microL sample buffer, and 10 microL protein extract 
c. 5 microL sample buffer and 15 microL protein extract 
3. Pipette 10 microL of each concentration into different aliquots, label, and heat at 95 
degrees C for 5 minutes 
4. While tubes are heating, open gel and rip off bottom sticker. Place in gel box with clips 
near top on either side.  
5. Pour 1x Running buffer between wall and gel, as well as on the bottom 
6. Quickly centrifuge tubes after heating 
7. Pipette contents of each tube into separate wells of gel 
8. Plug machine in and turn to volts. Plug cap onto set up and machine (black to black, red 
to red). Set to ~106 volts (can be changed with center dial). Turn on machine and run for 





1. Make Transfer Buffer and fill Transfer box with Transfer Buffer 
2. Open transfer mechanism (white slider) and lay open. 
3. Dunk sponge in transfer buffer and place on open mechanism. Then dunk transfer paper 
and place on mechanism 
4. Cut membrane from roll w/ gloved hands to approximate size of gel (touch as little as 
possible). Dunk membrane and remove paper on either side of membrane. Place on open 
mechanism and roll out air bubbles with pipette tip 
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5. Remove gel from case by running scoopula between plastic until it cracks off. Place gel 
on saran wrap. Use razor to cut off wells. Place gel on open mechanism. 
6. Dunk second transfer paper and place on mechanism. Then dunk second sponge and 
place on mechanism. Close mechanism and place in transfer box. 
7. Turn on machine (like running a gel) and run for ~1 hour 
8. Once finished, remove and throw away gel 
9. Make block solution. Move transfer paper to tupperware container and pour Blocking 
Solution over transfer paper until it is covered. Place in cold room on rocker for ~2 hours. 
Can be stored in 1x TBS at 4 degrees C.  
 
Immunohistochemistry 
1. Block blots in blocking solution for 1-2 hours at RT on shaker 
2. Add primary antibody diluted in block solution 
3. Incubate overnight at 4 degrees C on shaker 
4. Rinse with TBST (make fresh) 3x 5 minutes at RT 
5. Add secondary antibody diluted in either block solution or TBST 
6. Incubate for 1 hour at RT. Cover if using fluorescently tagged antibody. 
7. Rinse with TBST 3x 10 minutes at RT. Cover if using fluorescently tagged antibody. 
8. Image immediately 
 
BCA Protein Kit Assay 
Preparation of Standards 
1. Prepare diluent - equal parts 2x Protease Inhibitor and RIPA buffer 
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2. Break ampoule - file around etching, get all liquid to bottom, hold between 
thumbs and forefingers with forefingers touching, break towards you 
3. Pipette according to Table 1 making sure to minimize bubbles 
a. Be sure to mix dilutions before taking from them for further 
dilutions 
 
 Table 1. Preparation of standards 
Tubes Volume of Diluent 
(microL) 
Volume and Source of 
BSA (microL) 
Final BSA Concentration 
(microg/mL) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of tube B 750 
E 325 325 of tube C 500 
F 325 325 of tube E 250 
G 325 325 of tube F 125 
H 400 100 of tube G 25 
I 400 0 0 = blank 
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Preparation of Working Reagent 
1. Determine total volume required 
 (# of standards + # of unknowns) x (# of replicates) x (volume per sample) = total 
volume WR required 
2. Mix 50 parts Reagent A with 1 part Reagent B 
 
Preparation of Sample Diluents 
1. Mix 1 part sample with 100 parts of 2x Protease Inhibitor and RIPA solution 
2. Mix 1 part sample with 10 parts of 2x Protease Inhibitor and RIPA solution 
 
Microplate Procedure 
1. Pipette 10 microL of standard or sample into individual wells according to Table 2 
 
Blank A B C D E F G H X1 X2 X3 
Blank A B C D E F G H X1 X2 X3 
 
2. Add 200 microL of WR to each well being careful to minimize bubbles 
3. Place film on top and mix on plate shaker for 30s 
4. Incubate at 37 C for 30 min 
a. Incubation time can be increased to up to 2 hours to increase sensitivity, if necessary 
5. Cool plate to RT and place in microplate reader 
6. Save run to USB in .xlsx format and analyze in excel 
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11. Make 2x RIPA Buffer, 2x Protease Inhibitor, 5x Sample Buffer, and 10x Running Buffer 
before beginning process (See recipe list). Put homogenizer on ice. Begin heating block 
to 95 degree C if using protein extract immediately 
12. Add Tricaine to petri dish w/ larvae (see tricaine procedure on wall) 
13. Transfer larvae to eppendorf tube and remove excess E3 buffer 
14. Mix 70 microL Protease Inhibitor and 70 microL 2x RIPA buffer to separate eppendorf 
tube (for 30 bros) 
15. Add ~120 microL of RIPA mixture to eppendorf containing larvae 
16. Remove larvae and RIPA mixture and add to homogenizer on ice 
17. Homogenize larvae 
18. Remove homogenized larvae and place in eppendorf 
19. Centrifuge for 30 minutes at 13000 G at 4 degree C 
20. Remove supernatant and place in new eppendorf tube. This can either be used 
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1. Fresh or thawed supernatant should be aliquoted into an Eppendorf tube at 100 ul and add 
***concentration of antibodies*** were to the sample 
2. Add 30 ul of 1:1 slurry of protein-A sepharose beads in NET buffer to sample 
a. Bead slurry should be made before immunoprecipitation is begun  
i. Swell needed amount of beads in NET buffer on ice for 45 min-2h, until 
beads settle 
ii. Pipette off excess buffer and add fresh buffer at the original volume. 
Allow beads to settle. Keep on ice. 
iii. Pipette off excess buffer and add NET buffer at a volume equal to the 
settled bead bed. Keep on ice. Bead slurry can be kept at 4ºC for one week 
3. Centrifuge immunoprecipitation samples 1 min 
4. Aspirate buffer 
5. Wash with 1 ml cold NET buffer 
6. Repeat steps 3-5 
7. Repeat steps 3 and 4, wash with 1 ml cold 0.01 M Tris, pH 6.7 
8. Centrifuge samples for 1 min 
9. Aspirate buffer 
10. Add 30 ul running buffer and either use immediately for SDS-PAGE or store at -20ºC 
 
SDS-PAGE 
1. Add 1x Running Buffer to gel apparatus 
2. Pipette 11 ul of Marker and samples into individual wells of SDS-PAGE gel 
3. Run at 106 volts for one hour  
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4. Remove gel from case and immediately begin silver stain procedure 
 
Silver Stain 
1. Immerse gel in 100 ml Fixative, place on a shaker at 60-70 rpm for 20 min 
a. Prepare Fixative by mixing 50 ml ethanol with 10 ml glacial acetic acid and 40 ml 
deionized water 
2. Wash gel in 100 ml 30% ethanol, place on shaker at 60-70 rpm for 10 min 
a. Prepare 30% ethanol by mixing 30 ml ethanol with 70 ml deionized water 
3. Wash gel in 100 ml deionized water, shake at 60-70 rpm for 10 min 
4. Incubate gel in 100 ml Silver Stain Sensitizer Working Solution 
a. Prepare Silver Stain Sensitizer Working Solution by mixing 1 ml Silver stain 
Sensitizer with 99 ml deionized water. Use within two hours after preparation 
5. Wash gel in 200 ml deionized water and shake at 60-70 rpm for 1 minute. Replace water 
and shake for an additional minute 
6. Incubate gel in 100 ml Silver Stain Working Solution and shake at 60-70 rpm for 20 
minutes 
a. Prepare Silver Stain Working Solution by adding 1 ml Silver Stain with 99 ml 
deionized water. Use within two hours after preparation. 
7. Wash gel in 100 ml deionized water and shake at 60-70 rpm for 30 seconds. Replace 
water and shake for an addition 30 seconds 
8. Add 100 ml Developer Working Solution and shake at 60-70 rpm until protein bands 
appear (~3-10 minutes) 
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a. Prepare Developer Working Solution by adding 20 ml Silver Stain Developer B 
into 80 ml deionized water and 0.05 ml of Silver Stain Developer A 
9. When desired band intensity is achieved, replace Developer Working Solution with Stop 
Solution. Shake at 60-70 rpm for 10 minutes 
a. Prepare stop solution by mixing 5 ml glacial acetic acid with 95 ml deionized 
water 
10. Replace Stop Solution with deionized water. Shake at 60-70 rpm for 2-5 minutes 
11. Image immediately and store at 4ºC 
 
UVP Imaging System Set Up and Image Processing Protocol 
1. Biolite source set up 
Bulb - redlight 
Intensity - max at 6 
Filter Position - 2, blue light 
  1, green light 
Fiber Optic light - Epi 
Emission Filter - 1 w/ green light 
  2 w/ blue light 
2. Acquisition set up 
 Lens: 
  Aperture - 2.1 
  Zoom - ~25 
  Focus - far side 
 Max out gain in preview window 
 Capture image 
3.Image Processing Set Up 
Under Image tab 
Histogram 
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 Stretch mode to ‘Automatic’ 
Corrections  
 Brightness - 15 
 Contrast - 60 
 Gamma - 1.9 
 
Densitometry Analysis Procedure 
Piasecki, Cell Bio 
1. Open immunoblot image: file → open → immunoblot.tif 
2. Convert RGB image to an 8-bit B/W image so that you can quantify pixel intensity 
(image → type → 8-bit) 
3. Subtract the background (Process → subtract background) using light background at 
50 pixel radius 
4. Invert the image to make protein light (higher pixel values) and background dark 
(lower pixel values) – (Edit → Invert) 
5. Make sure  the measurement “integrated density is selected” (Analyze → Set 
Measurements → Integrated Density) 
6. Use box tool to select and measure both background and protein bands. 
a. Select the box tool from the clipboard (Far left) 
 
b. Using your mouse select a region surrounding the largest protein band. 
c. Using the keyboard press command M (alternatively select Analyze → 
Measure) 
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d. Using your cursor, select inside the yellow square and move the box to a new 
region of the image; press command M. 
e. Repeat the previous step until the integrated density of both the top and 
bottom bands of each of the three wells, as well as two or three background 
values, have been analyzed.  
f. Place this information into a spreadsheet, subtract the average background 
band from each of your individual top and bottom band measurements, and 
determine the ratio of the top and bottom bands from each background 
corrected value. 
 
 
 
